alexa Escitalopram Response in Panic Disorder is Not Associated with Three 5-HT1A Receptor Gene Polymorphisms (Rs6295, Rs10042486, or Rs1364043) in Chinese-Han Patients

ISSN: 2167-1044

Journal of Depression and Anxiety

  • Research Article   
  • J Depress Anxiety 2017, S12-006
  • DOI: 10.4172/2167-1044.S12-006

Escitalopram Response in Panic Disorder is Not Associated with Three 5-HT1A Receptor Gene Polymorphisms (Rs6295, Rs10042486, or Rs1364043) in Chinese-Han Patients

Wenhui C1, Qian L2, Suxia C2, Jianyue P2 and Hengfen L2*
1Department of Psychiatry, Shenyang Mental Health Center, Shenyang 110168, Liaoning Province, P.R. China
2Department of Psychiatry, The First Affiliated Hospital ofZhengzhou University, Zhengzhou 450002, Henan Province, P.R. China
*Corresponding Author: Hengfen L, Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450002, Henan Province, P.R. China, Tel: +8637166913114, Email: [email protected]

Received Date: Oct 04, 2017 / Accepted Date: Oct 25, 2017 / Published Date: Oct 27, 2017

Abstract

Background: Prior studies have implicated 5-HT1A receptor gene (HTR1A) polymorphisms in the etiology of panic disorder (PD) as well as in the therapeutic response to selective serotonin reuptake inhibitors (SSRIs). A functional HTR1A C-1019G polymorphism (rs6295) in the promoter region and two non-synonymous polymorphisms (rs10042486 and rs1364043) were previously found to be associated with SSRI pharmacogenetics. However, no studies have examined this relationship in Chinese-Han PD patients.
Methods: Seventy-seven patients with PD according to DSM-IV criteria were recruited. All of them with a minimum score of 8 on the seven item Panic Disorder Severity Scale, Chinese version (PDSS-CV). In this study, we evaluated the association between three single nucleotide polymorphisms (SNPs) of HTR1A (rs6295, rs10042486, and rs1364043) and the clinical effects of escitalopram in Chinese-Han PD patients.
Results: The C/C genotype of C-1019G carriers showed better responses to escitalopram compared to the C/G or G/G genotypes. However, after Bonferroni correction, the effect was not statistically significant. Similarly, no significant associations were noted between rs10042486 or rs1364043 and the escitalopram clinical response.
Conclusion: Our results suggest that these three single nucleotide polymorphisms (SNPs) in 5-HT1A genes examined here may not influence the escitalopram response in Chinese-Han PD patients.

Keywords: 5-HT1A receptor gene; Single nucleotide polymorphism; Panic disorder; Escitalopram

Introduction

Panic disorder (PD) is a common anxiety disorder that affects up to 5% of the population over their lifetime [1]. In addition, PD has been linked to increased cardiovascular morbidity and mortality, which typically increases the burden of suffering as well as economic costs [2,3]. Therefore, it is valuable to determine its etiology and provide targeted treatment methods for this disorder.

Positron emission tomography (PET) analyses have found significantly reduced 5-HT1A radio ligand binding in the raphe nuclei, orbitofrontal cortex, temporal cortex, and amygdala regions of PD patients compared to control subjects [4]. Moreover, genetic studies suggest the involvement of the 5-HT1A receptor gene in panic disorder [5]. Animal studies have demonstrated that 5-HT1A receptor knockout mice show increased anxiety-like behavior [6]. Thus, based on neuroimaging data, animal models, and genetic studies, the 5-HT1A receptor gene, located on chromosome 5 (5q11.2–13), is a putative candidate gene for PD [7]. Of several gene polymorphisms, studies have focused on a functional C-1019G single nucleotide polymorphism (SNP rs6295) located in the promoter of HTR1A, which regulates HTR1A transcription, and is associated with schizophrenia, bipolar disorder, anxiety, depression-related personality traits, and antidepressant responses [8-10]. In particular, two very recent studies reported the C-1019G polymorphism was associated with clinical responses in Japanese and Caucasian PD patients [11,12]. Additionally, this polymorphism and a nearby functional polymorphism are in strong linkage disequilibrium [13]. Based on these results, we hypothesized that other HTR1A polymorphisms in strong linkage disequilibrium with rs6295 might also influence the clinical response. Two polymorphisms of HTR1A (rs10042486 and rs1364043) were previously found to be associated with SSRI pharmacogenetics. However, no association study of HTR1A gene polymorphisms (rs6295, rs10042486, and rs1364043) and escitalopram clinical response in Chinese-Han PD patients has been reported.

Therefore, we conducted an association study with three HTR1A gene SNPs (rs6295, rs10042486, and rs1364043) to determine the best predictive value for clinical responses in Chinese-Han PD patients.

Methods

Subjects

This study was performed at Shenyang Mental Health Center. The Ethics Committee of Shenyang Mental Health Center approved this study, and each subject provided written informed consent before enrollment. Seventy-seven patients (24 males, 53 females) with PD according to DSM-IV criteria were recruited.

Only subjects with a minimum score of 8 on the seven item Panic Disorder Severity Scale, Chinese version (PDSS-CV) qualified for the study. Patients with substance abuse, severe organic mental disorders, or concomitant major psychiatric disorders were excluded. The mean age of patients was 30.61±6.51 years (± SD) and ranged from 18 to 60 years. The clinical response to treatment was assessed using the PDSSCV at the beginning of treatment and every two weeks thereafter. It took 5 to 7 days before patients received the full therapeutic escitalopram dose (10-20 mg/day). A significant clinical response was defined as a 50% decrease in PDSS-CV total score within 4 weeks of escitalopram treatment.

Polymorphism genotyping

Genomic DNA was extracted from EDTA-treated venous blood using standard techniques and DNA extraction kits (Wizard Genomic DNA purification kit; Promega, USA). Genotyping for the three SNPs (rs6295, rs10042486, and rs1364043) was performed using polymerase chain reaction (PCR) and post-PCR ligase detection reaction (LDR) assays. Genomic DNA was amplified using the following primers: rs6295 (sense: 5′-ACGGAGGTACCGTTTTGTTG-3′, antisense: 3′-CCCAGAGTGGCAATAGGAGA- 5′), rs10042486 (sense: 5′-GGTTGGAGTTTCTCAGTAATTGG- 3′, antisense: 3′-TGGGGATTGGGAAGAATTAAA- 5′), rs1364043 (sense: 5′-AAGCGAACTCAAACAGCAAAA-3′, antisense: 3′-TTTGAAGAGGGCACAATTCC-5′). PCR reactions had a final volume of 20 μl containing 100 ng genomic DNA, dNTPs (0.2 mM of each), 1.0 ng/l template, 2.0 mM PCR buffer, 0.6 mM Mg2+, 0.2 U/ml HOT Start Taq DNA polymerase, 9.8 μl H2O, 4 μl Q-solution, and 0.4 pM primer mix. After an initial denaturation step of 15 min at 95°C, DNA was amplified by 35 cycles of denaturation at 94°C for 30 s, annealing at 53°C for 1 min, and extension at 72°C for 1 min, followed by a final extension step at 72°C for 10 min. Successful amplification was confirmed by running 2 μl of the PCR product mixture on agarose gels stained with ethidium bromide.

LDR assays were performed in a final volume of 10 μl containing ≥1 μl PCR products, 6.95 μl H2O, 0.05 μl ligase, 1 μl probe mix, and 1 μl buffer. The initial denaturation for 2 min at 95°C was followed by 35 cycles of denaturation at 94°C for 30 s and annealing and extension at 60°C for 2 min. LDR products were used for allele discrimination. LDR products were denatured at 95°C for 2 min and mixed with 1 μl of the size standard ABI GS-500 ROX (Applied Biosystems Inc., USA). The products were electrophoresed in 10% polyacrylamide with 5 M carbamide at 3000 V for approximately 2.5 hours. GENESCAN TM 672 software was used to collect data, correct the line of electrophoresis, and measure different fragments. Genemapper software was used to analyze the genotype distributions.

Statistical analysis

We used chi-square analyses or Fisher’s tests to compare escitalopram clinical responses with genotype frequencies. Fisher’s exact tests were substituted for chi-square tests when sample size was smaller than five subjects. Independent-sample t-tests were used to evaluate differences in PDSS-CV scores, age, and escitalopram doses between the response and non-response groups during the 4 weeks of treatment. For multiple comparisons, Bonferroni correction was applied using the formula: a’=a/k, Where a’ is the corrected significance level for multiple comparisons, a is the significance level (0.05) and k is the number of independent significance tests. Statistical analyses were performed using the SPSS 17.0 software package.

Results

The genotype distributions of all 5-HT1A gene polymorphisms were in Hardy-Weinberg equilibrium (p>0.05). The mean age, escitalopram dose, and PDSS-CV score of the responders and non-responders are presented in (Table 1) These two groups showed no significant differences in PDSS-CV scores at baseline, age, or escitalopram dose (p>0.05).

Variables Responders Non-responders t p
Age 29.03 ± 6.79 31.56 ± 6.40 -1.67 0.10
Escitalopram dose 16.55 ± 3.80 17.50 ± 2.73 -1.27 0.21
PDSS score (baseline) 20.97 ± 2.21 21.08 ± 2.00 -0.24 0.81
PDSS score (week 2) 17.07 ± 1.91 17.48 ± 2.05 -0.87 0.39
PDSS score (week 4) 10.24 ± 1.02 12.00 ± 1.41 -5.83 <0.01

Table 1: The mean age, escitalopram dose, and PDSS score between responders and non-responders in PD patients.

The genotype distributions for the three SNPs in the responders and non-responders after 4 weeks of escitalopram treatment are shown in (Table 2) The C/C genotype of C-1019G showed better response to escitalopram, compared to the C/G and G/G genotypes (χ2=6.79, p=0.04). However, this difference was not significant after adjusting the significance level for multiple tests (for k=3 groups and k × (k-1)/2=3 comparisons, the corrected significance level is 0.017). Similarly, no statistically significant differences in rs10042486 and rs1364043 genotype distributions were noted between the two groups (χ2=0.54, p=0.83 for rs10042486, χ2=0.78, p=0.70 for rs1364043).

Genotype Responders [n (% )] Non-responders [n (% )] χ2 p
rs6295
GG 13 (30.2) 30 (69.8) 6.79 0.04
CG 9 (36.0) 16 (64.0)
CC 7 (77.8) 2 (22.2)
rs10042486
CC 1 (33.3) 2 (66.7) 0.54 0.83
CT 11 (42.3) 15 (57.7)
TT 17 (35.4) 31 (64.6)
rs1364043
GG 10 (35.7) 18 (64.3) 0.78 0.70
GT 17 (41.5) 24 (58.5)
TT 2 (25.0) 6 (75.0)

Table 2: Genotype distributions in the responders and non-responders after escitalopram treatment for 4 weeks.

Discussion

To the best of our knowledge, this is the first study to evaluate the relationship between the three HTR1A gene SNPs and SSRI clinical response in Chinese-Han PD patients. In the present study, we not only compare the genotypes distribution in responders and nonresponders group, but also adopt genotype-time interaction model to further explore the differences in PDSS Scale changes according to 5-HT1A polymorphisms over time. Our finding failed to detect any association either rs6295, rs10042486 and rs1364043 of the HTR1A gene polymorphism and antidepressant response or differences in PDSS-CV Scale changes according to 5-HT1A polymorphisms after 4 weeks of escitalopram treatment in Chinese-Han PD patients.

The 5-HT1A receptor gene is located both presynaptically (as an auto receptor) and post-synaptically (as a heteroreceptor). The auto receptor exerts a negative feedback function and when stimulated by 5-HT, induces hyperpolarization of 5-HT neurons and decreases the neuronal firing rate, thereby resulting in decreased 5-HT synthesis and release. The 5-HT1A heteroreceptor is involved in mediating 5-HT actions on target neurons receiving serotonergic innervation. Thus, it has the dual ability to modulate global serotonin levels as well as local responses to released serotonin [7,14].

The functional C-1019G SNP rs6295, located in the 26 bp palindromic sequence of the HTR1A promoter, may influence HTR1A transcription activity by binding two transcription factors: deformed epidermal auto regulatory factor-1 (Deaf-1) and hairy enhancer of split 5 (Hes5). It was reported that the transcription factors Deaf-1 and Hes5 can repress expression of the 5-HT1A auto receptor by binding the C-allele but not the G-allele [15-18]. Therefore, the G-1019 allele correlates with increased levels of 5-HT1A auto receptors. A brain imaging study also found that the G allele and 5-HT1A receptor binding increases in both the raphe nuclei and other brain regions [19]. Therefore, this could cause a greater extent of desensitization of 5-HT1A auto receptors, reduce raphe firing, decrease serotonin release, and confer resistance to SSRIs [20,21]. In contrast, in cells expressing 5-HT1A post synoptically, Deaf-1 activity is opposed in presynaptic versus postsynaptic neuronal cells. Thus, Deaf-1 activates 5-HT1A transcription by binding to the C allele but not the G allele [20,21]. Therefore, the G-1019 allele might reduce Deaf-1-enhanced postsynaptic 5-HT1A transcription as well as enhance resistance to antidepressant-induced increases in 5-HT [15,16]. Thus, it is reasonable to speculate that the G/G genotype could result in worse clinical responses unless SSRI treatment activates 5-HT neurons more strongly in these patients due to extensive desensitization of overexpressed autoreceptors. In agreement with this, Yevtushenko and co-authors found that the C allele of rs6295 showed substantial symptom improvement in Caucasian PD patients [12]. Ishiguro et al. also found that Japanese PD patients who were rs6295C/C carriers showed improved clinical response to paroxetine pharmacotherapy compared to non-carriers [11].

Several factors could account for these discrepancies. First, the rs6295 polymorphism may be in linkage disequilibrium with another genetic variation polymorphisms within the 5-HT1A promoter region that are causally related to antidepressant response, and it can also be speculated that the linkage disequilibrium of rs6295 with other polymorphisms within the 5-HT1A gene may not be same for all ethnic populations, thus may help explain the previous inconsistent results. Second, the GG genotype distributions can differ markedly between populations and this difference can influence the statistical power. For example, in the study of Ishiguro, rs6295G/G genotype distributions were 3.1%, while the distributions were 19.6% in the study of Yevtushenko [11,15]. Third, the promoter region sequences of 5-HT1A have not been fully elucidated, the DNA sequences of promoter region may also differ by ethnic background, this influence the interaction of multiple cis and trans elements controlling 5-HT1A transcription result in the different expressions of 5-HT1A either in auto receptor or hetero receptor result in contributing to influence clinical response.

We did not observe an association between rs10042486 or rs1364043 and escitalopram response. One reason may be because the sequences of the 5-HT1A gene promoter region may differ in ethnic populations. Thus, the linkage disequilibrium of rs6295, rs10042486, and rs1364043 may not be the same in all ethnic backgrounds. Consequently, rs10042486 and rs1364043 may not be involved in regulating HTR1A transcription, and subsequently do not influence the clinical response. In addition, even if rs10042486 and rs1364043 are in fact involved in the development of PD, these polymorphisms may not affect the size of the clinical effect.

One limitation of this study is the rather small sample size. Thus, we cannot evaluate sex and subclinical factors to elucidate their role in clinical responses. Further studies should examine sex and sub clinical interactions to fully explore their role in clinical responses. A second limitation is the absence of a placebo control, it is generally accepted that the placebo response plays a significantly role in the therapeutic response to antidepressant agents and thus we cannot exclude the possibility that some PD patients in the responder group responded to the placebo response alone [22]. The lack of a placebo control limits whether the observed associations were directly attributed to drugrelated genetic or other biological factors [23-26].

Conclusion

In summary, our study indicates that 5-HT1A genetic variation isn’t associated with escitalopram response. However, studies with larger sample sizes in different ethnic backgrounds may be necessary to fully elucidate the nature of this relationship.

Acknowledgment

This study was supported by the National Natural Science Foundation of China (81371494).

Conflict of Interest

All authors declare that they have no conflicts of interest.

References

Citation: Wenhui C, Qian L, Suxia C, Jianyue P, Hengfen L (2017) Escitalopram Response in Panic Disorder is Not Associated with Three 5-HT1A Receptor Gene Polymorphisms (Rs6295, Rs10042486, or Rs1364043) in Chinese-Han Patients. J Depress Anxiety S12: 006. Doi: 10.4172/2167-1044.S12-006

Copyright: © 2017 Wenhui C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Recommended Conferences
  • International Child & Adult Behavioural Health Conference

    September 13-14, 2018 Dubai, UAE

  • 12th World Congress on Advances and Innovations in Dementia

    September 17-18, 2018 Singapore City, Singapore

  • 30th International Conference on Mental and Behavioral Health

    November 12-13, 2018 Melbourne, Australia

  • 5th International Conference on Depression , Anxiety and Stress Management

    November 05-06, 2018 Bangkok, Thailand

Article Usage
  • Total views: 661
  • [From(publication date): 0-2017 - May 21, 2018]
  • Breakdown by view type
  • HTML page views: 629
  • PDF downloads: 32

Post your comment

captcha   Reload  Can't read the image? click here to refresh
Leave Your Message 24x7